The U.S. Department of Health and Human Services (HHS) said on Wednesday it signed a deal with British drugmaker AstraZeneca Plc to develop antibiotics.
The federal agency said it will share costs with AstraZeneca to develop a portfolio of drugs to treat illnesses caused by bioterrorism agents and antibiotic-resistant infections.
The Biomedical Advanced Research and Development Authority of the HHS will initially provide $50 million, and could pay up to $170 million for development of additional products as part of the deal, which is for five years.
Help employers find you! Check out all the jobs and post your resume.
